<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00139581</url>
  </required_header>
  <id_info>
    <org_study_id>CASM981C2314</org_study_id>
    <nct_id>NCT00139581</nct_id>
  </id_info>
  <brief_title>Comparison of Pimecrolimus Cream 1% Twice-Daily to Once-Daily Dosing in the Management of Atopic Dermatitis in Pediatric Subjects</brief_title>
  <official_title>Comparison of Pimecrolimus Cream 1% Twice-Daily to Once-Daily Dosing in the Management of Atopic Dermatitis in Pediatric Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      This study is not being conducted in the United States.

      To investigate the relative efficacy of pimecrolimus cream 1% applied twice daily (b.i.d.)
      versus once daily (o.d.) in preventing the progression to disease &quot;relapse&quot;.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2004</start_date>
  <completion_date type="Actual">September 2005</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to relapse of atopic dermatitis (defined as the exacerbation of atopic dermatitis to the level where a topical corticosteroid or alternative therapy is required).</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Investigators Global Assessment (IGA) and pruritus (itch) assessment of atopic dermatitis at time of suspected relapse</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to first recurrence of atopic dermatitis</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Eczema Area and Severity Index (EASI) and IGA assessments at several time points.</measure>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <condition>Atopic Dermatitis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pimecrolimus b.i.d.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pimecrolimus o.d. and placebo o.d.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pimecrolimus</intervention_name>
    <description>Pimecrolimus cream 1 % applied twice daily (b.i.d.)</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Elidel b.i.d.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pimecrolimus</intervention_name>
    <description>Pimecrolimus cream 1 % applied once daily (o.d.) and placebo applied once daily (o.d.)</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Elidel o.d.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria - Screening/Run-In Period

          -  age &gt;= 2 years through age &lt;=17 years of age

          -  IGA score of 2, 3, or 4 (mild, moderate, or severe AD) affecting &gt;5% TBSA

          -  outpatients

        Exclusion Criteria:Screening/Run-In period

          -  subjects who applied topical therapy (e.g. tar, topical corticosteroids) within 2
             weeks prior to Screening

          -  subjects who received phototherapy (e.g. UVB, PUVA, Narrow Band) within 4 weeks of
             Screening

          -  subjects who received any systemic immunosuppressant

          -  subjects who received systemic steroids

          -  females who are pregnant or breast-feeding, or planning to become pregnant during the
             study

          -  subjects who are immunocompromised (e.g. lymphoma, AIDS, Wiskott-Aldrich syndrome) or
             have a history of malignancy (includes basal cell carcinoma, squamous cell carcinoma,
             melanoma)

          -  subjects with open skin infections (bacterial, viral or fungal) if at the application
             site.

          -  subjects will HSV (common cold sores) are allowed to participate in the study (if not
             at the application site).

          -  subjects who have head lice or scabies

          -  subjects who present with clinical conditions other than AD that may interfere with
             the evaluation (e.g., generalized erythroderma, acne, Netherton's Syndrome,psoriasis)

          -  subjects that require systemic therapy for the treatment of atopic dermatitis

          -  subjects with poor or no clinical response to tacrolimus ointment (ProtopicÂ®) or
             pimecrolimus cream 1%

          -  subjects who used any experimental or investigational drug or therapy within 6 weeks
             prior to Screening

          -  subjects who intend to use experimental or investigational drug therapy during the
             course of this study

          -  subjects with known hypersensitivity to pimecrolimus 1% or related drugs (see
             Investigator's Brochure)

          -  subjects who are non-compliant with general medical treatment, or are known to miss
             appointments, or don't intend to comply with the protocol for the duration of the
             study

          -  drug abuse, mental dysfunction, or other factors limiting the subject's ability to
             cooperate fully with study-related procedures

          -  subjects known to be unreliable or may be unable to complete the study

          -  any condition or prior/present treatment that would render the subject ineligible for
             the study

        Inclusion criteria - Double-blind Maintenance treatment period

        - Achieve complete remission of active disease (no signs or symptoms of AD) without
        incidence of &quot;relapse&quot; by the end of 6-week Run-In period (may be earlier); or who achieve
        &quot;disease improvement&quot; (decrease in IGA score by 1 full point confirmed by the investigator)
        without incidence of relapse at the end of the 6-week Run-In period

        Exclusion criteria - Double-blind Maintenance treatment period

          -  subjects who experienced a &quot;relapse&quot; during the Run-In period

          -  subjects who applied topical corticosteroids or any alternative or additional therapy
             for the treatment of AD during the Run-In period

          -  subjects with active skin infections (bacterial, viral or fungal) except common cold
             sores (HSV) at the application site

          -  subjects who failed to record study medication use (and non use) and dosing regimen
             during the Run-In period

          -  subjects who failed to apply open label study drug twice daily until &quot;disease
             remission&quot; or end of the 6 week Run-In period

          -  subjects who failed to record concomitant medications during the Run-In period

          -  failure to return open-label study drug (used, partially used, and unused tubes) at
             the time double-blind study drug is dispensed. In order to avoid medication error, all
             open label study drug must be returned to the site before starting the Maintenance
             period
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharma AG</last_name>
    <role>Study Chair</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>This study is not being conducted in the United States</name>
      <address>
        <city>Novartis Pharma AG</city>
        <state>Basel</state>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>April 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 30, 2005</study_first_submitted>
  <study_first_submitted_qc>August 30, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2005</study_first_posted>
  <last_update_submitted>April 22, 2008</last_update_submitted>
  <last_update_submitted_qc>April 22, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 23, 2008</last_update_posted>
  <responsible_party>
    <name_title>External Affairs</name_title>
    <organization>Novartis</organization>
  </responsible_party>
  <keyword>Atopic dermatitis, children, infants, pimecrolimus, bid, od</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pimecrolimus</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

